0001213037-26-000013
SEC filingCardiff Oncology reported Q1 2026 financial results with reduced operating expenses and cash of $46.1M sufficient into Q1 2027, alongside positive clinical progress including FDA alignment on Phase 3 trial design for onvansertib.
Cardiff Oncology's Q1 2026 results reflect disciplined cost management, with total operating expenses dropping to $12.9 million from $14.5 million year-over-year, driven by a $3.7 million reduction in R&D expenses from lower clinical trial and preclinical costs, offset by $2.1 million higher SG&A due to severance and stock option modifications. This contributed to a narrower net loss of $12.3 million or $0.18 per share versus $13.4 million or $0.20 per share in Q1 2025. Cash burn eased to $12.3 million from $12.8 million, preserving a $46.1 million liquidity position sufficient into Q1 2027, supporting upcoming milestones without immediate dilution risk. CEO Mani Mohindru highlighted clinical momentum, including January's Phase 2 CRDF-004 topline data showing 72.2% ORR and superior PFS (HR 0.38) for 30mg onvansertib + FOLFIRI/bev versus standard care in first-line RAS-mutated mCRC, with no added toxicity. The successful End-of-Phase 2 FDA meeting in April locked in this regimen for the Phase 3 registrational trial, with details forthcoming mid-2026. ASCO presentation of updated data and preclinical synergy with T-DXd bolster the PLK1 inhibition strategy. Leadership bolstering with permanent CEO Mohindru, new CFO Muntner, and COO Aggarwal positions the company for execution amid high-unmet-need mCRC market.